Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial

Randall J. Bateman, Yan Li, Eric McDade, Jorge J. Llibre‐Guerra, David B. Clifford, Alireza Atri, Susan L. Mills, Anna Santacruz, Guoqiao Wang, Charlene Supnet, Tammie L.S. Benzinger, Brian A. Gordon, Laura Ibáñez, Gregory Klein, Monika Baudler, Rachelle S. Doody, Paul Delmar, Geoffrey A. Kerchner, Tobias Bittner, Jakub Wojtowicz, Azad Bonni, Paulo Fontoura, Carsten Hofmann, Luka Kulic, Jason Hassenstab, Andrew J. Aschenbrenner, Richard J. Perrin, Carlos Cruchaga, Alan E. Renton, Chengjie Xiong, Alison A Goate, John C Morris, David M. Holtzman, B. Joy Snider, Catherine J. Mummery, William S. Brooks, David Wallon, Sarah Berman, Erik D. Roberson, Colin L. Masters, Douglas Galasko, Suman Jayadev, Raquel Sánchez‐Valle, Jérémie Pariente, Justin Kinsella, Christopher H van Dyck, Serge Gauthier, Ging‐Yuek Robin Hsiung, Mario Masellis, Bruno Dubois, Lawrence S. Honig, Clifford R. Jack, Alisha Daniels, David Aguillón, Ricardo Allegri, Jasmeer P. Chhatwal, Gregory S. Day, Nick C. Fox, Edward D. Huey, Takeshi Ikeuchi, Mathias Jucker, Jae‐Hong Lee, Allan I. Levey, Johannes Levin, Francisco Lopera, Jee Hoon Roh, Pedro Rosa‐Neto, Peter R. Schofield